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doi:10.1016/j.ijgo.2006.08.004Abstract Polycystic ovary syndrome is a multi-system endocrinopathy with long-
term metabolic and cardiovascular health consequences. Patients typically present
due to symptoms of irregular menstruation, hair growth, or infertility; however,
recent management options are aimed at further treating underlying glucose–insulin
abnormalities as well as androgen excess for proactive control of symptoms. By a 2003
international consensus conference, diagnosis is made by two out of three criteria:
chronic oligoovulation or anovulation after excluding secondary causes, clinical or
biochemical evidence of hyperandrogenism (but not necessarily hirsutism due to
inter-patient variability in hair follicle sensitivity), and radiological evidence of
polycystic ovaries. Traditional medical treatment options include oral contraceptive
pills, cyclic progestins, ovulation induction, and anti-androgenic medications
(aldosterone antagonist, 5α-reductase antagonist, and follicle ornithine decarbox-
ylase inhibitor). Recent pharmacotherapies include insulin-sensitizing medications
metformin and two thiazolidinediones (rosiglitazone/Avandia® and pioglitazone/
Actos®), a CYP19 aromatase inhibitor (letrozole/Femara®), and statins to potentially
lower testosterone levels.
© 2006 International Federation of Gynecology and Obstetrics. Published by
Elsevier Ireland Ltd. All rights reserved.KEYWORDS
Polycystic ovaries;
Insulin resistance;
Insulin sensitizing
medicines1. Definition
Perhaps the earliest text on polycystic ovary syndrome
(PCOS) was described by Antonio Vallisneri as “…Youngof Obstetrics and Gyne-
x 0617, 1150 West Medical
rbor, MI 48109-0617, USA.
8617.
ich.edu (S.E. Domino).
6 International Federation ofpeasant woman, married, moderately plump, infer-
tile, with ovaries larger than normal, like doves' eggs,
lumpy, shiny and whitish” in 1721 [1]. The inherent
variability of PCOSwas evident even in the initial Irving
Stein and Michael Leventhal description in 1935 in
their series of patients showing polycystic ovaries, but
with other characteristics exhibited non-uniformly,
including infertility, hirsutism, and oligomenorrhea
[2]. The first international consensus on the clinical
criteria for PCOS was held in 2003 by the EuropeanGynecology and Obstetrics. Published by Elsevier Ireland Ltd.
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the American Society for Reproductive Medicine, at
Rotterdam, Netherlands [3]. The consensus definition
requires two of the following three criteria, highlight-
ing the range of clinical expressions within the
disorder.
1. Polycystic ovaries: 12 or more follicles in an ovary,
with each follicle measuring 2–9 mm in diameter
and/or ovarian volume N10 ml. Neither stromal
density nor distributionof the follicles is included in
this revised definition. One polycystic ovary is
sufficient for diagnosis.
2. Oligo-/anovulation: clinically diagnosed as oligo-/
amenorrhea, i.e., menstrual cycles longer than
35 days or less than 10 menstruations per year.
3. Hyperandrogenism: clinical or biochemical.
Note that the criteria for PCOS do not apply to
adolescent girls, women using contraceptive steroid
pills, or postmenopausal women. The diagnosis of
PCOS requires the exclusion of other conditions,
including congenital adrenal hyperplasia, non-classic
congenital adrenal hyperplasia, Cushing syndrome,
acromegaly, androgen-secreting tumors, hyperprolac-
tinemia or prolactinoma, primary hypothyroidism,
premature ovarian failure, or drug effects from
exogenous androgens. It has been shown that trans-
abdominal and transvaginal ultrasound examinations
correlate well; thus, both are acceptable tools for
diagnosis, and the choice of which to use can be left to
the clinician [4]. In menstruating women, ultrasound
examination is most sensitive when performed on the
third, fourth, or fifth day of the menstrual cycle.
2. Prevalence and pathogenesis
The reported incidence of PCOS ranges from 3% to
11% varying by the diagnostic criteria used and the
population studied [5]. The prevalence would be
expected to be higher with the expanded Rotterdam
criteria, as confirmed in one study that demon-
strated a prevalence of 12% [6], and further prev-
alence studies are needed using the Rotterdam
criteria.
2.1. Evolution and anthropology
The complexity of PCOS continues to make under-
standing its pathogenesis a difficult task. Its
etiology is only poorly understood, and many
theories of pathogenesis have been proposed. It
has been hypothesized that during evolutionary
history, it may have been advantageous for a woman
to be hyperandrogenic and have increased insulinresistance [7]. Insulin resistance may have en-
hanced a woman's ability to store energy as
subcutaneous fat when food was abundant, improv-
ing her chances for survival when food was scarce.
2.2. Genetic and environmental factors
Heterogeneous phenotypes and lack of a universally
accepted definition of PCOS have made genetic
studies difficult. There is evidence to support an
autosomal dominant genetic model with low pene-
trance [8]. Genes that have been postulated to be
involved in the development of PCOS include the
CYP17A gene, which encodes for the P450c 17α
enzyme, the CYP11A gene, which encodes for the
P450 side-chain cleavage enzyme, the insulin gene,
and variable number tandem repeat/VNTR
sequences [9]. Mothers of women with PCOS have
dyslipidemia, hyperandrogenemia, and serum mar-
kers of insulin resistance [10]. Multiple genes seem
to be implicated, and polygenic inheritance is likely
responsible for the majority of cases.
2.3. Enhanced serine phosphorylation
unification theory
A theory of pathogenesis that serves as a link between
hyperandrogenism and insulin resistance is the en-
hanced serine phosphorylation unification theory
[11]. Serine phosphorylation of the P450c 17α enzyme
enhances its 17,20-lyase activity, leading to increased
androgen synthesis within the theca cell. One of the
principal mediators of the insulin signaling pathway is
insulin receptor substrate-1 (IRS-1). Serine phosphor-
ylation of various sites on IRS-1 leads to decreased
activity of themediator when insulin signaling occurs,
blunting the normal transport of glucose into the cell.
The body responds to this relative hyperglycemia with
hyperinsulinemia.
Insulin stimulates androgen synthesis in both the
ovaries and in the adrenal glands [12]. Insulin acts
synergistically with luteinizing hormone and aug-
ments steroid synthesis in the ovaries, which leads
to follicle arrest and anovulation [13]. Insulin also
inhibits the production of sex hormone binding
globulin in the liver leading to higher levels of
serum-free testosterone.
3. Treatment
3.1. Non-pharmacologic treatment
The diversity of the clinical presentation and
pathophysiology of PCOS is mirrored by the numer-
ous treatment options. The various treatments can
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manifestations of hyperandrogenemia, those that
restore regular ovulation and menstruation, and
those that affect insulin resistance. Treatments in
one of these categories are not limited to effects
only in its own category [14].
Weight loss of only 5–7% has been shown to
improve manifestations of hyperandrogenism, de-
crease hyperinsulinemia, and restore ovulation and
fertility in up to 75% of women [15]. There is no
evidence that any particular diet regimen is more
beneficial than another for PCOS women.
Utilizing ovarian drilling or diathermy, ovulation
can be restored in 80% of women, and the pregnancy
rate is 50% in women who are treated with surgery
[16]. Laparoscopic ovarian diathermy has been
shown to be safe and cost-effective for treating
clomiphene-resistant PCOS [17].
3.2. Treatment for acne and hirsutism
Treatments for acne and hirsutism in PCOS indivi-
duals strive to decrease serum androgen levels, by
lowering androgen production or by increasing
androgen binding to plasma-binding proteins, and
to block androgen activity in the target tissue [14].
Contraceptive steroid pills, specifically estrogen–
progestin combination therapy, are used by many
clinicians as the first-line treatment for acne and
hirsutism in individuals with PCOS who do not desire
immediate fertility. The estrogen suppresses lutei-
nizing hormone release from the pituitary, which
suppresses ovarian androgen production [14]. Es-
trogen also increases hepatic production of sex
hormone-binding globulin, decreasing the unbound
serum testosterone. Though oral contraceptive pills
will improve acne, hirsutism, and protect against
endometrial hyperplasia due to unopposed estro-
gen, this method of treatment does not positively
affect insulin resistance [18,19].
In patients in whom treatment with oral contra-
ceptive pills may be contraindicated (e.g., smokers
above age 35, individuals with a history of thrombotic
disease), progestins may be givenmonthly or every 2–
3 months to prevent endometrial hyperplasia. This
treatment will not affect hirsutism, acne, or improve
insulin resistance.
Antiandrogen treatments are also used to combat
acne and hirsutism. Used predominantly in Canada,
Mexico, and Europe, cyproterone acetate competi-
tively inhibits the binding of testosterone and 5α-
dihydrotestosterone to the androgen receptor [20]
and effectively treats hirsutism and acne. Antiandro-
gen treatments that are utilized in the United States
include spironolactone and finasteride. Drospirenone
is an analogue of spironolactone with some anti-mineralocorticoid and antiandrogenic activity; it is
available in combination with estradiol in the oral
contraceptive pill Yasmin® or Yaz® (Berlex Labora-
tories Inc., Monteville, NJ 07045 USA) [21]. When
used in higher doses (∼100–200 mg/day), spirono-
lactone has moderate antiandrogenic effects. It
inhibits steroidogenic enzymes and binds the dihy-
drotestosterone receptor at the hair follicle [22].
Side effects include irregular uterine bleeding.
Contraception is required during administration of
spironolactone (pregnancy category D). Use of spiro-
nolactone during pregnancy is contraindicated, as it
leads to incomplete virilization of male fetuses. As
the drug has been found to have synergistic effects
when combined with oral contraceptive pills, these
two are often prescribed simultaneously [14].
Flutamide, a nonsteroidal antiandrogen, is effec-
tive in the treatment of hirsutism, but concern about
the side effect of liver dysfunction has blunted its
widespread use [23]. Finasteride is a competitive
inhibitor of the enzyme type 2 5α-reductase, and
systemic use has been shown to decrease circulating
dihydrotestosterone and to treat hirsutism [24].
Topical use is not effective since type 1 5α-reductase
is present in the pilosebaceous unit [14]. Because the
use of finasteride during the first trimester increases
risks of hypospadias in male fetuses, contraception is
alsomandatory with this drug (pregnancy category X).
Eflornithine hydrochloride (Vaniqa®; SkinMedica
Inc., Carlsbad, CA 92008, USA) is a topical medication
approved for use in treating facial hirsutism. It inhibits
ornithine decarboxylase, a critical enzyme in initiat-
ing cell division, and thus, it acts in the follicle to
disrupt hair growth [25]. It requires 4–8 weeks of
treatment for results and is a pregnancy category C
drug. Clinical data in PCOS women is limited.
The above therapies will all target hair in the long
term. They may take as long as 6–9 months to have
maximal effects, and discontinuation of each drug is
associated with recurrence of hirsutism. In the short
term, patients should be counseled to pursue more
direct methods of removing hair. Laser hair removal
delivers thermal injury to the follicle by targeting the
follicular melanin [26]. It works best in individuals
with light skin and dark hair, but it may cause pigment
changes in the skin. It should be avoided in patients
who tend to form keloids or hypertrophic scars.
3.3. Drug treatment to restore ovulation/
fertility
Lowering insulin levels by improving insulin sensitiv-
ity improves ovulation, restores menstruation, and
improves fertility, as well as symptoms of hyperan-
drogenemia [27,28]. Thus, insulin-sensitizing agents
are subjects of continued research on improving
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factors associated with hyperinsulinemia, in PCOS
women. The research supporting these drugs will be
presented in the next section.
Ovulation rates up to 80% contrast with pregnancy
rates of 30–40% in cycles with or without clomiphene
citrate (CC) in PCOS women [29]. Adding metformin
increases ovulation rate and conception rate com-
pared to CC alone [30]. Newer ovulation induction
agents include the aromatase inhibitors such as
letrozole (Femara®; Novartis Pharmaceutical Corp.,
East Hanover, NJ 07936 USA). Letrozole is a non-
steroidal inhibitor that binds reversibly to the heme
group of aromatase CYP19. Its primary use is for
adjuvant treatment of postmenopausal women with
hormone receptor positive early breast cancer (preg-
nancy category D). In the setting of PCOS, by
decreasing estrogen production, it leads to an
increase in follicle stimulating hormone (FSH) release
by the pituitary, without the ill-toward anti-estrogen-
ic properties of CC. Increased FSH then leads to
follicular development and eventual ovulation. Com-
paredwith CC, letrozolemay (1) decrease the number
of mature follicles, (2) decrease the risk of ovarian
hyperstimulation syndrome, and (3) increase the rates
of both ovulation and pregnancy [31]. In a randomized
trial in CC-resistant PCOS women on metformin,
letrozole led to a higher delivery rate than continued
CC therapy [32]. Side effects include hot flashes,
nausea, hair thinning, arthralgia, myalgia, and arthri-
tis, although side effects have not been shown to
affect compliance, a problem seenmore frequently in
CC recipients.
3.4. Therapies that affect insulin resistance
The French lilac or Goat's rue plant (Galega
officianlis) was used to treat diabetes mellitus in
medieval times [33]. It was determined that the
plant contained guanidine, which had anti-hyper-
glycemic properties, and is structurally related to
biguanides, one of which is metformin. Metformin
was marketed in Europe starting in 1979, and it was
approved for use by the United States in 1995. Due
to the history of lactic acidosis in this class, it is
avoided in individuals with kidney or liver disease,
in situations that increase the risk for lactic
acidosis, and before or after procedures when
patients will receive an intravenous dye load.
Metformin is widely used today in patients with
type II diabetes mellitus and with PCOS, but the exact
mechanism by which it functions remains a mystery.
What is known is that it both enhances peripheral
uptake and inhibits hepatic glucose production; thus,
it is an anti-hyperglycemic rather than a hypoglycemic
agent [34]. Significantweight reduction has been seenwith metformin therapy [35]. Its side effects include
nausea, diarrhea, abdominal discomfort, metallic
taste, and anorexia, which can occur in up to 20% of
patients. Side effects can be reduced by taking the
drug withmeals and by increasing the dose slowly. It is
pregnancy class B, and one study has not found an
adverse affect on growth or motor-social develop-
ment in the first 18 months of life [36].
Metformin has been shown to be effective in
ovulation induction as the sole agent and in conjunc-
tion with CC [30,37]. The presence of insulin
resistance is a positive predictor of metformin
response in PCOS women [38]. Long-term therapy
with metformin decreases progression from insulin
resistance to frank diabetes mellitus in PCOS women,
but short-term therapy of as little as 2 weeks helps to
improve ovulation and fertility [39,40].
Three thiazolidinediones have been used in clinical
practice: troglitazone (Rezulin®; Parke-Davis/Warn-
er-Lambert, now Pfizer, Inc., New York, NY 10017,
USA), rosiglitazone (Avandia®; GlaxoSmithKline, Re-
search Park Triangle, NC 27709, USA), and pioglita-
zone (Actos®; Tekada Pharmaceuticals America, Inc.,
Lincolnshire, IL 60069, USA, and Eli Lilly and Company,
Indianapolis, IN 46285, USA). Troglitazone was with-
drawn from the market due to hepatic toxicity in
2000. The thiazolidinediones work as selective ago-
nists for nuclear peroxisome proliferator-activated
receptor-γ (PPAR-γ). Binding to PPAR-γ activates
genes that regulate carbohydrate and lipid metabo-
lism, and the drugs' principal effects are to increase
insulin sensitivity in peripheral tissue and lower
glucose production by the liver [41]. Because of the
history of this class of drugs, liver enzymes are
generally monitored during therapy with thiazolidi-
nediones.Metabolismoccurs in the liver; rosiglitazone
by CYP2C8, pioglitazone by both CYP3A4 and CYP2C8.
Studies with troglitazone in PCOS women showed
improvements in insulin resistance, hyperandrogen-
emia, and glucose tolerance [42]. Ovulation was
significantly increased, free testosterone levels de-
creased, and levels of sex hormone-binding globulin
increased. Though troglitazone is no longer available,
studies with rosiglitazone and pioglitazone have
demonstrated similar results [43,44]. The drugs are
pregnancy class C. Because they work by different
mechanisms, thiazolidinediones and metformin may
be used together in type II diabetes mellitus. Further
researchwill need to be done to determine the effects
of this combination in individuals with PCOS.
3.5. Statin medications
Statins are a novel therapeutic approach to PCOS
and have shown promise in early in vitro studies as
well as a single prospective, randomized trial.
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tial cells had diminished proliferation and steroido-
genesis [45]. A clinical trial compared simvastatin
plus oral contraceptive pills to an oral contraceptive
group alone [46]. The statin group showed signifi-
cantly lowered testosterone levels and normalized
gonadotropin levels; however, there was no signif-
icant difference between the groups on the Ferri-
man-Gallway scale, which is used to quantify the
severity of a patient's hirsutism.
4. Future directions and research
The realization that PCOS is intimately linked to
insulin resistance and the host of metabolic problems
associated with type II diabetes mellitus, especially
the increased risk of cardiovascular disease, has led to
a shift in paradigm in the treatment of this syndrome.
Traditional treatment focused on reproductive and
aesthetic issues. PCOS is now recognized as a
multisystem syndrome with long-term health conse-
quences. Induction of ovulation and control of
hyperandrogenic symptoms has been augmented by
the use of insulin-sensitizing drugs.
The controversies of the expansion of the
Rotterdam criteria will require research into those
women who were not previously included as PCOS
patients to determine if treating them with the
same drugs and protocols is safe and advantageous.
Further research into the enhanced serine phos-
phorylation theory may lead to drugs that target
these phosphorylation sites.
While studies have shown combined therapy with
metformin and CC to be superior to CC alone in PCOS
women and letrozole to be superior to CC alone in
PCOS women, there are no studies that look at the
effects of combining metformin with letrozole. Such
a protocol may give patients the long-term benefits
of controlling insulin levels along with the short-
term benefits of increased FSH secretion and
regular ovulation and menstruation.
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